Amgen – $3.38 Earnings Per Share Anticipated for Amgen Inc. (NASDAQ:AMGN) This Quarter
Equities analysis analysts forecast that Amgen Inc. (NASDAQ:AMGN) will submit earnings per share (EPS) of $3.38 for the present fiscal quarter, Zacks reviews. 9 analysts have supplied estimates for Amgen’s earnings. The bottom EPS estimate is $3.09 and the best is $3.64. Amgen posted earnings per share of $3.64 in the identical quarter final 12 months, which signifies a unfavorable year-over-year progress fee of seven.1%. The corporate is scheduled to report its subsequent quarterly earnings outcomes after the market closes on Tuesday, February 2nd.
On common, analysts anticipate that Amgen will report full-year earnings of $16.15 per share for the present fiscal 12 months, with EPS estimates starting from $15.89 to $16.44. For the following monetary 12 months, analysts forecast that the enterprise will submit earnings of $17.00 per share, with EPS estimates starting from $15.97 to $18.07. Zacks’ earnings per share calculations are a imply common primarily based on a survey of analysts that observe Amgen.
Amgen (NASDAQ:AMGN) final posted its quarterly earnings outcomes on Monday, November 2nd. The medical analysis firm reported $4.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.75 by $0.62. The agency had income of $6.42 billion for the quarter, in comparison with analysts’ expectations of $6.38 billion. Amgen had a internet margin of 29.42% and a return on fairness of 95.55%.
AMGN has been the topic of a number of latest analysis reviews. The Goldman Sachs Group lowered shares of Amgen from a “conviction-buy” ranking to a “purchase” ranking in a analysis notice on Tuesday, December 15th. Mizuho lowered their goal price on shares of Amgen from $260.00 to $215.00 and set a “impartial” ranking for the corporate in a analysis notice on Monday, November 2nd. Bank of America lowered their goal price on shares of Amgen from $275.00 to $265.00 and set a “purchase” ranking for the corporate in a analysis notice on Thursday, October 29th. Oppenheimer assumed protection on shares of Amgen in a analysis report on Sunday, December 27th. They set a “purchase” ranking and a $266.00 price goal for the corporate. Lastly, Credit score Suisse Group lowered their price goal on shares of Amgen from $286.00 to $284.00 and set an “outperform” ranking for the corporate in a analysis report on Tuesday, October 27th. One funding analyst has rated the stock with a promote ranking, twelve have assigned a maintain ranking and eighteen have assigned a purchase ranking to the stock. The stock presently has a consensus ranking of “Purchase” and a mean price goal of $254.92.
In different information, Director Ronald D. Sugar bought 1,00Zero shares of the enterprise’s stock in a transaction on Wednesday, January 13th. The shares have been bought at a mean price of $235.99, for a complete transaction of $235,990.00. Following the transaction, the director now straight owns 16,805 shares within the firm, valued at roughly $3,965,811.95. The transaction was disclosed in a submitting with the SEC, which is accessible at this hyperlink. Additionally, Director R Sanders Williams bought 250 shares of the enterprise’s stock in a transaction on Monday, November ninth. The shares have been bought at a mean price of $242.40, for a complete transaction of $60,600.00. Following the transaction, the director now owns 4,909 shares within the firm, valued at $1,189,941.60. The disclosure for this sale may be discovered right here. Insiders personal 0.36% of the corporate’s stock.
Institutional buyers have lately purchased and bought shares of the corporate. Advisory Alpha LLC acquired a brand new stake in shares of Amgen within the third quarter valued at $25,000. JFG Wealth Administration LLC acquired a brand new stake in shares of Amgen within the third quarter valued at $28,000. Norway Financial savings Bank acquired a brand new stake in shares of Amgen within the 4th quarter valued at $29,000. Baron Monetary Group LLC acquired a brand new stake in shares of Amgen within the third quarter valued at $51,000. Lastly, Paces Ferry Wealth Advisors LLC acquired a brand new stake in shares of Amgen within the third quarter valued at $52,000. Institutional buyers and hedge funds personal 75.23% of the corporate’s stock.
AMGN traded up $3.83 throughout buying and selling on Monday, hitting $245.49. The corporate had a buying and selling quantity of 176,840 shares, in comparison with its common quantity of two,573,000. The corporate has a debt-to-equity ratio of three.12, a present ratio of two.28 and a fast ratio of 1.88. Amgen has a 1-year low of $177.05 and a 1-year excessive of $264.97. The enterprise has a 50-day transferring common of $229.04 and a 200-day transferring common of $238.54. The corporate has a market cap of $142.92 billion, a PE ratio of 19.80, a P/E/G ratio of 1.84 and a beta of 0.76.
The enterprise additionally lately declared a quarterly dividend, which will likely be paid on Monday, March eighth. Stockholders of report on Monday, February 15th will likely be issued a dividend of $1.76 per share. This can be a increase from Amgen’s earlier quarterly dividend of $1.60. This represents a $7.04 annualized dividend and a dividend yield of two.87%. The ex-dividend date is Thursday, February 11th. Amgen’s payout ratio is presently 43.18%.
Amgen Firm Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on irritation, oncology/hematology, bone well being, heart problems, nephrology and neuroscience areas. The corporate’s merchandise embody Enbrel to deal with plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to deal with most cancers sufferers; Prolia to deal with postmenopausal girls with osteoporosis; Xgeva for skeletal-related occasions prevention; Aranesp to deal with a lower-than-normal variety of purple blood cells and anemia; KYPROLIS to deal with sufferers with relapsed or refractory a number of myeloma; Sensipar/Mimpara to deal with secondary hyperparathyroidism; and EPOGEN to deal with anemia attributable to continual kidney illness.
Additional Studying: What does a impartial ranking on stocks imply?
Get a free copy of the Zacks analysis report on Amgen (AMGN)
For extra details about analysis choices from Zacks Funding Analysis, go to Zacks.com
This immediate information alert was generated by narrative science know-how and monetary information from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to [email protected]